Can somatostatin control acute bleeding from oesophageal varices in Schistosoma mansoni patients?

Submission date 30/11/2004	Recruitment status No longer recruiting	[X] Prospectively registered	
		[X] Protocol	
Registration date	Overall study status	Statistical analysis plan	
01/12/2004	Completed	[] Results	
Last Edited 06/11/2019	Condition category Infections and Infestations	Individual participant data	
		[] Record updated in last year	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Prof Eric Van Marck

Contact details

Head of Pathology University of Antwerp Antwerp Belgium B-2610

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers Nil known

Study information

Scientific Title

Can somatostatin control acute bleeding from oesophageal varices in Schistosoma mansoni patients?

Study objectives

Schistosomiasis is a disease causing liver fibrosis leading to portal hypertension and oesophageal varices that can cause fatal bleeding.

Given the background that somatostatin is an ideal vasoactive drug in the field of liver pathology, it is our opinion that somatostatin will be more efficacious and safe as compared to currently used beta blocker drugs like propanolol, in the control of acute oesophageal variceal bleeding due to Schistosoma mansoni infection. Moreover using this neuropeptide may increase time to failure of drug treatment, decrease incidences of early re-bleeding (day 4, 8) and incidences of death during the follow up period. Decreased frequencies of late rebleeding (days 30, 60, 90) may occur, all indicating the safety of using somatostatin. Praziquantel cover would be given to all study patients.

Ethics approval required Old ethics approval format

Ethics approval(s) Not provided at time of registration

Study design Randomised controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Not specified

Study type(s) Treatment

Participant information sheet

Health condition(s) or problem(s) studied Schistosomiasis

Interventions

Intervention: Intravenous (IV) infusion with somatostatin consisting of one bolus and infusion for 24 hours.

Control: Standard care, which is a beta blocker propanolol.

To study end results, questionnaires and sonography will be used.

Intervention Type

Drug

Phase Not Specified

Drug/device/biological/vaccine name(s)

Somatostatin, propanolol, praziquantel

Primary outcome measure

The primary efficacy variable is the number of patients meeting the failure of therapy definition during the infusion period. Failure criteria are defined as death during infusion, persistence of active bleeding (The haemodynamic instability criteria points to the inability to achieve and maintain a systolic blood pressure of 80 mmHg OR presence of a 20 mmHg drop in systolic blood pressure from the highest post resuscitation value AND achieving a heart rate of 120 bpm OR a 20 bpm increase from highest post resuscitation value OR inability to achieve and maintain a Hct of 27% of Hb of 9 g/dl despite blood transfusion of 2 units or more.

The clinical criteria of active bleeding include hematemesis (fresh or semi fresh blood), hematochezia, melena.

Secondary outcome measures Not provided at time of registration

Overall study start date

01/01/2006

Completion date 31/12/2006

Eligibility

Key inclusion criteria

Schistosoma mansoni infected adolescent patients with variceal bleeding in the last 24 hours.

The inclusion criteria will be established fibrosis due to schistosomiasis of clinical history, physical examination and laboratory findings (and an examination compatible with the presence of portal hypertension due to fibrosis). Clinically active upper gastrointestinal bleeding (haematemesis of fresh or semi fresh blood and/or melena and/or haematochezia) with or without haemodynamic instability (systolic blood pressure < 80 mm Hg and heart rate > 120 bpm) will be selected. Subjects must be male or non-pregnant, non-lactating female subjects. Females of childbearing potential will have to utilize contraception for the duration of the study. Written or verbal documented informed consent will be needed from all subjects.

Participant type(s)

Patient

Age group Child

Child

Sex Both

Target number of participants 20

Key exclusion criteria

Exclusion criteria will include participation by subjects in another investigational study within the last 14 days. Subjects may not undergo treatment with endotherapy, i.e. band ligation, sclerotherapy or other (balloon tamponade). Treatment with somatostatin, vasopressin or their analogues will also be a exclusion criteria. Subjects with end stage liver disease with hepatorenal syndrome, diffuse hepatocellular carcinoma, patent porto-systemic shunts, known diagnosis of non-fibrotic portal hypertension, severe cardiovascular diseases, i.e. acute myocardial infarction and heart failure will be excluded. Concurrent use of metoclopramide is also not advised.

Date of first enrolment 01/01/2006

Date of final enrolment 31/12/2006

Locations

Countries of recruitment Belgium

Study participating centre Head of Pathology Antwerp Belgium B-2610

Sponsor information

Organisation University of Antwerp (Belgium)

Sponsor details University of Antwerp Antwerp Belgium B-2610

Sponsor type University/education

ROR https://ror.org/008x57b05

Funder(s)

Funder type Industry

Funder Name

External funding for this protocol comes from UCB-Pharma, Brussels, Belgium who have gifted the somatostatin (Belgium)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs					
Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	Study protocol:	13/12/2004		Yes	No